Legend Biotech Announces Three New Appointments to the Board of Directors
June 09 2020 - 4:35PM
Business Wire
Legend Biotech (NASDAQ: LEGN) announced today that it has
appointed Dr. Corazon (Corsee) Dating Sanders, Dr. Darren Ji, and
Mr. Philip Yau to the company’s Board of Directors.
Dr. Sanders joined the Legend Biotech Board of Directors in May
2020. She has over 25 years of experience in the discovery and
development of biopharmaceutical products addressing high unmet
medical need disease areas. Dr. Sanders has directly contributed
and/or provided oversight in developing multiple pharmaceutical
products, including a CAR-T cell therapy for Non-Hodgkin lymphoma
when she served on the Juno Therapeutics Executive Committee as
Executive Vice President of Development Operations from 2017 to
2018 and as Strategic Advisor to the Celgene Chief Medical Office
from 2018 to 2019. She was also a Member of the Genentech/Roche
Late Stage Portfolio Committee from 2009 to 2017, and Global Head
of the Genentech/Roche Late Stage Clinical Operations, covering the
Americas, Europe, and Asia Pacific from 2012 to 2017.
Dr. Sanders currently serves as a member of the Board of
Directors of Molecular Templates, Inc and of AbGenomics
International, Inc.
Dr. Ji joined the Legend Biotech Board of Directors in May 2020
and will serve as Chairperson of the Compensation Committee. In
prior roles, he served as the Global Head and Vice President of F.
Hofmann-La Roche Ltd. for Business Development in Asia and Emerging
Markets. Dr. Ji was responsible for driving the strategy and
execution of business development activities in a large territory
encompassing over 100 countries.
A repeat entrepreneur, Dr. Ji started his career at Procter
& Gamble Pharmaceuticals with increasing responsibilities in
drug R&D and business development. He co-founded and managed as
CEO PharmaLegacy Laboratories in Shanghai in 2008, which became a
premium CRO providing high-quality drug discovery services to a
large global clientele until today.
Currently, Dr. Ji is Chairman and CEO of Elpiscience
Biopharmaceuticals, Inc., a clinical stage immunotherapy company
which he co-founded. He is also a Venture Partner of Lilly Asia
Ventures (LAV).
Mr. Yau joined the Legend Biotech Board of Directors in May 2020
and will serve as Chairperson of the Audit Committee. He has over
23 years of experience in accounting, finance, mergers and
acquisitions, investments, corporate finance, audit, and risk
management. Most recently, Mr. Yau served as the non-Executive Vice
Chairman and Group Chief Financial Officer at AMTD Group where he
led the strategy development, corporate finance and investment
function. Prior to that, he worked at Ernst & Young China
Practice as a partner and risk advisor China South market leader,
serving clients in Greater China. From January 2006 to July 2011,
he worked at Protiviti Shanghai Co., Ltd. serving clients in
Greater China, and as a managing director and Shenzhen office
leader, where he was primarily responsible for overall management
of the company. From 1997 to 2006, he worked at
PricewaterhouseCoopers and Arthur Andersen & Co. in various
roles with his most recent position as a senior manager in the risk
consulting practice.
”We are thrilled to welcome Corsee, Darren and Philip to our
Board of Directors at this exciting and important new phase of
evolution for Legend Biotech,” stated Dr. Yuan Xu, Board Member and
Chief Executive Officer of Legend Biotech. “The addition of these
directors complements our Board’s skills and experiences, and we
are confident they will provide valuable perspectives. We look
forward to their engagement and assistance in guiding our
strategies and objectives to bring innovative and impactful cell
therapies toward potential registration and commercialization.”
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical
company engaged in the discovery and development of novel cell
therapies for oncology and other indications. Our team of over 650
employees across the United States, China and Europe, along with
our differentiated technology, global development, and
manufacturing strategies and expertise, provide us with the strong
potential to discover, develop, and manufacture best-in-class cell
therapies for patients in need.
We are engaged in a strategic collaboration with Janssen Biotech
to develop and commercialize our lead product candidate,
LCAR-B38M/JNJ-4528, an investigational BCMA-targeted CAR-T cell
therapy for patients living with relapsed or refractory multiple
myeloma. This candidate is currently being studied in
registrational clinical trials.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Legend Biotech’s
strategies and objectives and the potential contributions of its
three new board members. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
factors discussed in the “Risk Factors” section of the preliminary
prospectus filed with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Legend Biotech specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Readers should not rely upon the information on this page as
current or accurate after its publication date.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200609005749/en/
Media: Deborah Wong, Executive Director, Strategic Marketing
& Corporate Communications, Legend Biotech
deborah.wong@legendbiotech.com or media@legendbiotech.com
Investor Relations: Jessie Yeung, Head of Corporate Finance and
Investor Relations, Legend Biotech jessie.yeung@legendbiotech.com
or investor@legendbiotech.com
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Jul 2023 to Jul 2024